Chad Messer News Today

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are...

Operator Good day. Thank you for standing by, and welcome to the G1 Therapeutics Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] I would now like to turn the conference over to your host, Mr. Will Roberts. Please go ahead, sir. William Roberts -- Vice President of Investor Relations & Corporate Communications T...

Operator Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions]. Following the presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir. Benjamin Church -- Head, Corporate Communications & Investor Relations Thank you, operator. Good morning and welcome to Esperions Second Quarter 2021 Financial Re...

CTIC earnings call for the period ending March 31, 2021.

Operator Welcome to the Q1 2021 Athenex, Inc. Earnings Conference Call. My name is Richard, and Ill be your operator for todays call. [Operator Instructions] I am now going to call over Mr. Steven Rubis, Senior Director, Investor Relations. Steven, you may begin. Steven Rubis -- Investor Relations Good morning, and thank you for joining our conference call. Today, we will provide an update on Athenexs business as well as a review of financial results for the first quarter of 2021. The news rel...

Markets Needham analyst Chad Messer maintained a Buy rating on Esperion (ESPR – Research Report) today and set a price target of $134.00. The company’s shares closed last Tuesday at $26.88, close to its 52-week low of $23.90. According to TipRanks.com, Messer is a 4-star analyst with an average return of 9.1% and a 47.8% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics. The word on ...

I-MAB (IMAB) Gets a Buy Rating from Needham In a report released today, Chad Messer from Needham assigned a Buy rating to I-MAB (IMAB – Research Report), with a price target of $75.00. The company’s shares closed last Monday at $64.01, close to its 52-week high of $65.94. According to TipRanks.com, Messer is a 4-star analyst with an average return of 8.0% and a 46.2% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceut...

Esperion Therapeutics Inc (ESPR) Q4 2020 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Esperion Therapeutics Inc (NASDAQ: ESPR) Popular Searches Operator Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that todays conference call may be recorded. I would now like to hand the conference call over to Ben Church, Investor Relations and Corporate Communications a...